Blood amyloid beta levels in healthy, mild cognitive impairment and Alzheimer's disease individuals: replication of diastolic blood pressure correlations and analysis of critical covariates.

Autor: Agustín Ruiz, Pedro Pesini, Ana Espinosa, Virginia Pérez-Grijalba, Sergi Valero, Oscar Sotolongo-Grau, Montserrat Alegret, Inmaculada Monleón, Asunción Lafuente, Mar Buendía, Marta Ibarria, Susana Ruiz, Isabel Hernández, Itziar San José, Lluís Tárraga, Mercè Boada, Manuel Sarasa

Publikováno v: PLoS ONE, Vol 8, Iss 11, p e81334 (2013)

Plasma amyloid beta (Aβ) levels are being investigated as potential biomarkers for Alzheimer's disease. In AB128 cross-sectional study, a number of medical relevant correlates of blood Aβ40 or Aβ42 were analyzed in 140 subjects (51 Alzheimer's dis

Externí odkaz: https://doaj.org/article/1144d95a6c12445f803e453f2c87a54d

Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study

Autor: Manuel Sarasa, Mar Buendía, Pablo Martinez-Lage, Mercè Boada, Oscar Sotolongo-Grau, Judith Romero, Inmaculada Monleón, Josep Munuera, Montserrat Alegret, Javier Arbizu, Isabel Hernández, Elena Prieto, Lluís Tárraga, Agustín Ruiz, Virginia Pérez-Grijalba, Fernando Guillen, Pedro Pesini, Itziar San-José, Leticia Sarasa

Publikováno v: Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-9 (2019)
Dadun. Depósito Académico Digital de la Universidad de Navarra
Consejo Superior de Investigaciones Científicas (CSIC)
Alzheimer's Research & Therapy
ALZHEIMERS RESEARCH & THERAPY
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu

BackgroundTo facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer’s disease, supportive biomarker information is necessary. This study was aimed to investigate the association of plasma amyloid-beta (Aβ)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48579370ed8e0d9131471b3ddaa53fbe
https://doaj.org/article/8ea557f727a645db9b4c9c8e9f242844

Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial

Autor: Mar Buendía, Leticia Sarasa, Octavio Rodriguez-Gomez, Inmaculada Monleón, Carla Abdelnour, Virginia Pérez-Grijalba, Josep Munuera, María Pascual-Lucas, Hassnae Badi, Mercè Boada, Iván Marcos-Campos, Ana-María Lacosta, Pedro Pesini, Diego Casabona, Lluís Tárraga, Asunción Lafuente, Itziar San-José, Manuel Sarasa, Jesús Canudas, Agustín Ruiz

Publikováno v: Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-13 (2018)

Background Immunotherapy targeting the amyloid-β (Aβ) peptide is a promising strategy for the treatment of Alzheimer’s disease (AD); however, none of the active or passive vaccines tested have been demonstrated to be effective to date. We have de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43050109efbefedc7191fcc3217fd290
http://link.springer.com/article/10.1186/s13195-018-0340-8

O1‐10‐03: an Active Anti‐AB40 Vaccine (ABVAC40) Proved to be Safe and Immunogenic in the Phase i Clinical Trial

Autor: Lluís Tárraga, Laura Núñez, Leticia Sarasa, Virginia Pérez-Grijalba, Pedro Pesini, Agustín Ruiz, Manuel Sarasa, I. Marcos, Ana M. Lacosta, Mercè Boada, Itziar San José

Publikováno v: Alzheimer's & Dementia. 12

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7385d8189242dd8736d5d1e97331ab0d
https://doi.org/10.1016/j.jalz.2016.06.348

Association between cell-bound blood amyloid-β(1 - 40) levels and hippocampus volume

Autor: Miguel Angel Tejero, Itziar San José, Joan Giménez, Virginia Pérez-Grijalba, Lluís Tárraga, Mercè Boada, Sergi Valero, Mar Buendía, Marta Ibarria, Pedro Pesini, Asunción Lafuente, Oscar Sotolongo-Grau, Manuel Sarasa, Agustín Ruiz, Isabel Hernández

Publikováno v: Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Alzheimer's Research & Therapy

Introduction The identification of early, preferably presymptomatic, biomarkers and true etiologic factors for Alzheimer’s disease (AD) is the first step toward establishing effective primary and secondary prevention programs. Consequently, the sea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a243db7f31c749ae66ae804e365e29ea
https://doi.org/10.1186/s13195-014-0056-3